Have you ever wondered why proper screening is considered one of the most important steps before EBOO therapy?
Because Extracorporeal Blood Oxygenation and Ozonation (EBOO) involves temporary extracorporeal circulation, patient safety depends heavily on identifying potential risk factors before treatment begins.
A comprehensive pre-EBOO screening protocol helps evaluate coagulation status, organ function, cardiovascular stability, inflammatory burden, and potential contraindications to ensure patients are appropriate candidates for therapy.
Introduction: The Importance of Proper Pre-Screening
Extracorporeal Blood Oxygenation and Ozonation (EBOO) represents a significant therapeutic intervention that requires meticulous patient screening to ensure safety and optimize outcomes.
As providers, our primary responsibility is to identify patients who may be at increased risk for adverse events during this extracorporeal circulation procedure.
This comprehensive guide outlines the essential laboratory panels and clinical assessments necessary for proper patient selection.
Key Safety Considerations in EBOO Screening
Understanding the physiological demands of EBOO helps contextualize why specific screening parameters are critical for patient safety.
Physiological Stressors of EBOO:
- Extracorporeal circulation: Temporary volume shifts and foreign surface contact
- Coagulation activation: Platelet activation and coagulation cascade engagement
- Oxidative stress: Controlled oxidative challenge as therapeutic mechanism
- Fluid and electrolyte shifts: Minor but significant fluid compartment changes
- Cardiovascular demands: Mild hemodynamic changes during treatment
Essential Pre-EBOO Blood Panels
Core Laboratory Assessment Protocol
These essential panels form the foundation of EBOO safety screening, providing comprehensive assessment of coagulation status, organ function, and hematological stability.
| Panel | Components | Timing |
|---|---|---|
| Coagulation Profile | PT/INR, aPTT, Fibrinogen, Platelet Count, Consider TEG | Within 30 days of first treatment |
| Comprehensive Metabolic Panel | Glucose, Renal Function, Liver Function, Electrolytes, Bilirubin | Within 30 days of first treatment |
| Complete Blood Count | Hemoglobin, Hematocrit, RBC Indices, WBC with Differential, Platelets | Within 30 days of first treatment |
| Specialized Markers | hs-CRP, NT-proBNP or BNP, TSH, G6PD | G6PD before first treatment |
Laboratory Testing Timeline and Frequency
| Laboratory Panel | Pre-Treatment Baseline | Follow-up Monitoring | Critical Action Levels |
|---|---|---|---|
| Coagulation Profile | Within 30 days of first treatment | Every 6 months for chronic therapy | INR >1.5, Platelets <50,000/μL |
| Comprehensive Metabolic Panel | Within 30 days of first treatment | Every 6 months | eGFR <30, ALT/AST >3x ULN |
| Complete Blood Count | Within 30 days of first treatment | Every 3–6 months | Hgb <10 g/dL |
| G6PD Screen | Before first treatment | Only if clinically indicated | Any deficiency |
Coagulation Profile (Critical Safety Panel)
The coagulation profile is the most critical safety panel for EBOO, as the procedure involves extracorporeal circulation with potential for both bleeding and thrombotic complications.
Prothrombin Time (PT/INR)
- Evaluates Factors I, II, V, VII, X
- INR >1.5 indicates increased bleeding risk
- Monitor patients on warfarin carefully
- Consider vitamin K status
Activated Partial Thromboplastin Time (aPTT)
- Evaluates Factors I, II, V, VIII, IX, X, XI, XII
- Prolonged aPTT suggests coagulation factor deficiencies
- Monitor patients on heparin or direct thrombin inhibitors
- Consider lupus anticoagulant if prolonged
Fibrinogen and Platelets
- Fibrinogen <150 mg/dL increases bleeding risk
- Very high fibrinogen may indicate hypercoagulable state
- Platelets <50,000/μL is a relative contraindication
- Platelets <20,000/μL is an absolute contraindication
Coagulation Parameter Interpretation Guide
| Parameter | Normal Range | Caution Range | Contraindication Range |
|---|---|---|---|
| INR | 0.9–1.1 | 1.2–1.5 | >1.5 |
| aPTT | 25–35 sec | 36–45 sec | >45 sec |
| Fibrinogen | 200–400 mg/dL | 150–199 mg/dL | <150 mg/dL |
| Platelets | 150–450 x10³/μL | 50–149 x10³/μL | <50 x10³/μL |
Comprehensive Metabolic Panel Assessment
The comprehensive metabolic panel provides essential information about renal, hepatic, and metabolic function—all critical for safe EBOO treatment given the procedure’s impact on fluid balance and oxidative stress handling.
Renal Function Assessment
- BUN and Creatinine for GFR estimation
- eGFR <60 mL/min requires caution
- eGFR <30 mL/min is a relative contraindication
- Electrolyte imbalances affect cardiac stability
Hepatic Function Evaluation
- ALT/AST >3x ULN suggests significant liver stress
- Albumin <3.0 g/dL indicates synthetic dysfunction
- Bilirubin elevation requires investigation
- Liver cirrhosis is a strong relative contraindication
Metabolic Parameters
- Fasting glucose >126 mg/dL suggests diabetes
- Poorly controlled diabetes requires optimization first
- Electrolyte abnormalities should be corrected before treatment
Complete Blood Count with Differential
The CBC provides critical information about oxygen-carrying capacity, immune status, and bleeding risk.
- Hemoglobin <10 g/dL requires evaluation
- WBC >11,000 may indicate infection or inflammation
- Platelets <50,000 significantly increase bleeding risk
- Significant hematologic abnormalities may require specialist consultation
Cardiac and Inflammatory Markers
These specialized markers provide additional layers of safety assessment, particularly for patients with cardiovascular risk factors or inflammatory conditions.
- NT-proBNP or BNP: Screens for undiagnosed heart failure
- hs-CRP: Assesses inflammatory burden and provides baseline tracking data
- TSH: Screens for severe thyroid dysfunction that may affect treatment safety
Disease-Specific and Additional Screening
Additional testing may include:
- G6PD Quantitative Assay
- Iron Studies
- Hepatitis B and C Serology
- HIV Screening
- Additional inflammatory markers when clinically indicated
Absolute and Relative Contraindications
Absolute Contraindications
- G6PD deficiency
- Active severe hemolysis
- Acute myocardial infarction within 30 days
- Unstable angina
- Acute stroke within 30 days
- Active severe bleeding
- Pregnancy
- Acute organ failure
- Active untreated infection
Relative Contraindications
- Moderate-to-severe anemia
- Thrombocytopenia
- Chronic kidney disease
- Liver cirrhosis
- Stable congestive heart failure
- Atrial fibrillation
- Active malignancy
- Autoimmune disease
- Anticoagulation therapy
Clinical Workflow and Decision Making
- Initial Clinical Assessment
- Essential Laboratory Testing
- Laboratory Review and Risk Stratification
- Specialist Consultation
- Clearance Decision and Documentation
- Patient Education and Consent
Conclusion: Ensuring Patient Safety
Comprehensive pre-treatment screening is the foundation upon which safe and effective EBOO therapy is built. The systematic approach outlined in this protocol helps ensure patients receive appropriate care while minimizing preventable adverse events.
Key Principles for Safe EBOO Practice:
- G6PD screening is non-negotiable
- Systematic assessment prevents errors
- Documentation supports quality care
- Specialist consultation strengthens decision-making
- Patient education improves safety
- Continuous improvement remains essential
By viewing pre-treatment screening as an integral component of EBOO therapy rather than a separate administrative task, providers can improve patient safety, optimize outcomes, and establish a stronger foundation for long-term therapeutic success.